Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CDKN2A loss Palbociclib chordoma sensitive detail...
CDKN2A loss Abemaciclib chordoma sensitive detail...
SMARCB1 negative Tazemetostat chordoma predicted - sensitive detail...
MLH1 negative Pembrolizumab chordoma sensitive detail...
MSH6 negative Pembrolizumab chordoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01407198 Phase I Nilotinib Nilotinib With Radiation for High Risk Chordoma Active, not recruiting USA 0
NCT02383498 Phase II GI-6301 The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma Unknown status USA 0
NCT02389244 Phase II Regorafenib A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Recruiting FRA 0
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Active, not recruiting USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT02989636 Phase I Nivolumab Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Active, not recruiting USA 0
NCT03083678 Phase II Afatinib Afatinib in Locally Advanced and Metastatic Chordoma Active, not recruiting ITA | GBR 1
NCT03110744 Phase II Palbociclib CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) Completed DEU 0
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting USA 0
NCT03623854 Phase II Nivolumab + Relatlimab Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma Active, not recruiting USA 0
NCT03647423 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Withdrawn USA 0
NCT03886311 Phase II Nivolumab + Talimogene laherparepvec + Trabectedin Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) Recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04246671 Phase Ib/II TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Recruiting USA 0
NCT04416568 Phase II Ipilimumab + Nivolumab Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT04965753 Phase I FHD-609 FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors Active, not recruiting USA | ITA | FRA | ESP 0
NCT05041127 Phase II Cetuximab Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Recruiting USA 0
NCT05286801 Phase Ib/II Atezolizumab + Tiragolumab Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Recruiting USA | CAN | AUS 0
NCT05407441 Phase Ib/II Ipilimumab + Nivolumab + Tazemetostat Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Recruiting USA 0